LXN Hopes To Stay In Charge of Diabetes Control Market With $57.5 Mil. IPO
This article was originally published in The Gray Sheet
Executive Summary
LXN's agreement to supply Bristol-Myers Squibb with the company's In Charge for expanded indications of the diabetes drug Glucovance will translate into greater sales of the home glucose monitoring system, according to an Oct. 16 initial public offering prospectus filed with the Securities and Exchange Commission.
You may also be interested in...
Inverness Broadens Glucose Monitoring Portfolio Via LXN Acquisition
Inverness Medical Technology's acquisition of privately held LXN Corp., and with it the InCharge GlucoProtein home test, expands the firm's presence in the Type 2 diabetes market.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.